What is the thermal exposure on a Changsha to Poland lane in summer?

Details up front: Changsha · Poland.

This is presented as though it settles something, and I am not convinced it does.

I have two documents that appear to disagree, which is what prompted this.

Which parts of this are informative and which are decoration?

The relevant detail is that the lyophilised solid is far more robust than anything anyone says about it, and the solution is far less robust. Most of the confusion in this area comes from advice about one being applied to the other.

Practical thermal arithmetic for a shipment: a single 250 g phase-change pack in a thin-walled polystyrene box holds sub-ten-degrees for roughly 24 to 48 hours in a 25 °C ambient, and considerably less at 35 °C. Any lane taking eight to fourteen days is therefore not temperature-controlled for most of its duration regardless of what was in the box, which is the argument for shipping the material lyophilised.

Specifically, on re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

The licensed semaglutide and tirzepatide presentations carry in-use periods of several weeks at room temperature in their labelling, which is the closest thing to real stability data in this space — and it applies to a buffered, surfactant-containing, preservative-containing formulation, not to a reconstituted research vial.

I would be careful about generalising across sequences. Stability is sequence-specific, and a rule derived from semaglutide will not transfer cleanly to a tri-agonist with different residues in different local environments.

The single highest-value change most people can make is buying a cheap logging thermometer, because it converts an assumption about their storage into a record.

Worth being precise here: degradation is not one process, and which one dominates depends on the condition you are asking about. In solution at refrigerated temperature the rate-limiting pathway is usually deamidation and hydrolysis; at room temperature aggregation overtakes them; frozen, the damage happens during the transitions rather than during the hold.

Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.

Stated carefully, the 28-day figure for a reconstituted preserved vial is microbiological, not chemical. Chemically, a well-behaved peptide at 5 mg/mL at 4 °C will typically lose well under a per cent of content per month. The reason to respect the date is bioburden, and bioburden is a function of how many times you have opened it, not of the calendar.

Where community-submitted samples with known thermal excursions have been tested at Janoshik or Medutest, the recurring finding is that lyophilised material tolerates warm transit far better than intuition suggests, while reconstituted material shipped warm does not. The asymmetry is consistent enough to plan around.

The practical rule is that time and temperature multiply, so shorten whichever one you control.

The honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.

The temperature dependence is roughly Arrhenius over the range that matters, which in practice means every ten degrees of increase roughly doubles to triples the rate. Ten days at thirty degrees is therefore comparable to something on the order of a month or two at four degrees — bad, but not the catastrophe it feels like when you open a warm parcel.

The Arrhenius relationship underpinning accelerated stability testing is the basis of ICH Q1A, which is why accelerated studies at 40 °C and 75 per cent relative humidity are used to predict shelf life at 25 °C. The same relationship lets you reason about a warm transit lane, with the same caveats about extrapolation.

The limitation is that you cannot detect slow aggregation by eye until it is well advanced, so a clear vial is weak evidence of an intact one.

Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.

A warm arrival is a reason to test, not automatically a reason to discard. Peptide degradation is kinetic — rate multiplied by time — and a few days at thirty degrees in the solid state is a small integral compared to weeks in solution.

Freeze-concentration is the mechanism people miss. As ice forms, everything that is not water is excluded into a shrinking unfrozen fraction, so the local concentration of peptide, buffer salts and preservative rises sharply. If the buffer components crystallise at different rates, local pH can shift by more than a unit. That is why a phosphate-buffered solution can behave badly on freezing while an unbuffered one is fine.

The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.

Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.

edited 4 Feb 2025 by loss_on_drying — clarified the distinction between purity and content